Nabilone for non-chemotherapy associated nausea and weight loss due to medical conditions : a review of the clinical effectiveness and guidelines

Cannabis has been used medically for its antiemetic, sedative, and analgesic effects and for its ability to stimulate appetite. The major psychoactive ingredient of cannabis is delta-9-tetrahydrocannabinol (THC). Nabilone is a synthetic cannabinoid analog of THC and is approved for use in Canada for...

Full description

Corporate Author: Canadian Agency for Drugs and Technologies in Health
Format: eBook
Language:English
Published: [Ottawa] Canadian Agency for Drugs and Technologies in Health 12 September 2014, 2014
Series:Rapid response report: summary with critical appraisal
Subjects:
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
Summary:Cannabis has been used medically for its antiemetic, sedative, and analgesic effects and for its ability to stimulate appetite. The major psychoactive ingredient of cannabis is delta-9-tetrahydrocannabinol (THC). Nabilone is a synthetic cannabinoid analog of THC and is approved for use in Canada for the treatment of severe nausea and vomiting associated with chemotherapy in adults over the age of 18 years. For its approved indication, nabilone (1 mg to 2 mg) is used short-term, administered the night before and one to three hours prior to chemotherapy and can be continued up to 24 hours following chemotherapy. A systematic review of randomized controlled trials (RCTs) found that 70% of patients undergoing chemotherapy who received cannabinoids had complete control of nausea compared to 57% of placebo patients (RR 1.21; 95% CI 1.03 to 1.42). As well, 66% of patients had complete control of vomiting with cannabinoids compared to 36% of patients treated with placebo (RR 1.84; 95% CI 1.42 to 2.38). Nabilone exerts its therapeutic effect by acting as an agonist at the CB1 cannabinoid receptor, a receptor that has a role in the regulation of nausea and vomiting, appetite, movement, and pain. As such, nabilone has the potential to be used "off-label" for a number of conditions, for example, in the management of nausea and vomiting attributed to factors other than chemotherapy. In addition, the appetite stimulating properties of cannabinoids have been used to manage problematic or excessive weight loss secondary to medical conditions, such as AIDS and cancers. This report will review the evidence of clinical effectiveness and safety of nabilone when used for the treatment of non-chemotherapy related nausea and vomiting and to manage weight loss attributed to medical conditions
Item Description:Title from PDF caption. - "CADTH rapid response service."
Physical Description:1 PDF file (16 pages) illustrations